Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

Phase 1 Not yet recruiting 14 enrolled Trellis Bioscience LLC National Institute of Allergy and Infectious Diseases (NIAID) · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.

Timeline

Start: 2026-10
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	calpurbatug	Monoclonal antibody	60 mg	Inhaled

Indications

No indication recorded.